SOPHiA GENETICS S.A.
SOPHiA GENETICS S.A. (SOPH) Financial Performance & Income Statement Overview
Analyze SOPHiA GENETICS S.A. (SOPH) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
SOPHiA GENETICS S.A. (SOPH) Income Statement & Financial Overview
View the income breakdown for SOPHiA GENETICS S.A. SOPH across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $17.78M | $17.73M | $15.85M | $15.81M |
| Cost of Revenue | $5.57M | $5.63M | $5.20M | $5.03M |
| Gross Profit | $12.21M | $12.10M | $10.65M | $10.78M |
| Gross Profit Ratio | $0.69 | $0.68 | $0.67 | $0.68 |
| R&D Expenses | $9.12M | $9.14M | $7.87M | $7.96M |
| SG&A Expenses | $19.13M | $20.52M | $18.19M | $17.84M |
| Operating Expenses | $28.24M | $29.55M | $26.02M | $25.80M |
| Total Costs & Expenses | $33.81M | $35.18M | $31.22M | $30.83M |
| Interest Income | $450000.00 | $1.89M | $267000.00 | $450000.00 |
| Interest Expense | $659000.00 | $1.91M | $0.00 | $0.00 |
| Depreciation & Amortization | $2.30M | $2.29M | $2.21M | $2.04M |
| EBITDA | -$13.93M | -$12.23M | -$13.15M | -$12.99M |
| EBITDA Ratio | -$0.78 | -$0.69 | -$0.83 | -$0.82 |
| Operating Income | -$16.04M | -$17.44M | -$15.41M | -$15.02M |
| Operating Income Ratio | -$0.90 | -$0.98 | -$0.97 | -$0.95 |
| Other Income/Expenses (Net) | -$846000.00 | $2.90M | -$2.90M | -$27000.00 |
| Income Before Tax | -$16.88M | -$14.54M | -$18.31M | -$15.03M |
| Income Before Tax Ratio | -$0.95 | -$0.82 | -$1.15 | -$0.95 |
| Income Tax Expense | $503000.00 | $616000.00 | $130000.00 | $161000.00 |
| Net Income | -$17.39M | -$15.16M | -$18.44M | -$15.19M |
| Net Income Ratio | -$0.98 | -$0.85 | -$1.16 | -$0.96 |
| EPS | -$0.26 | -$0.23 | -$0.28 | -$0.23 |
| Diluted EPS | -$0.26 | -$0.23 | -$0.28 | -$0.23 |
| Weighted Avg Shares Outstanding | $66.84M | $66.67M | $66.38M | $65.92M |
| Weighted Avg Shares Outstanding (Diluted) | $66.84M | $66.67M | $66.38M | $65.92M |
Over the last four quarters, SOPHiA GENETICS S.A. achieved steady financial progress, growing revenue from $15.81M in Q2 2024 to $17.78M in Q1 2025. Gross profit stayed firm with margins at 69% in Q1 2025 versus 68% in Q2 2024. Operating income totaled -$16.04M in Q1 2025, maintaining a -90% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$13.93M. Net income dropped to -$17.39M, with EPS at -$0.26. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan